Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -212.45% is 157% below its 5-year average of -82.70%, around the middle of its 5-year range (-461.11%–-17.53%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.79% above its 12-month average of -268.23%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -212.45%.
RETURN ON EQUITY (ROE)
-212.45%
RETURN ON EQUITY (ROE) AVG TTM
-268.23%
RETURN ON EQUITY (ROE) AVG 3Y
-140.10%
RETURN ON EQUITY (ROE) AVG 5Y
-82.70%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.79%
CURRENT VS 3Y AVG
-51.64%
CURRENT VS 5Y AVG
-156.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 659 covered companies
CURRENT VS SECTOR MEDIAN
-428.36%
vs the sector median at left
Werewolf Therapeutics, Inc.
Market Cap
$45.20M
Return on Equity (ROE)
-212.45%
TTM Avg
-268.23%
3Y Avg
-140.10%
5Y Avg
-82.70%
Market Cap
$45.37M
Return on Equity (ROE)
123.04%
TTM Avg
-60.38%
3Y Avg
-75.18%
5Y Avg
-82.51%
Market Cap
$44.32M
Return on Equity (ROE)
-260.45%
TTM Avg
-109.97%
3Y Avg
-78.03%
5Y Avg
-56.14%
Market Cap
$44.31M
Return on Equity (ROE)
-288.49%
TTM Avg
-102.07%
3Y Avg
-71.41%
5Y Avg
-78.05%
Market Cap
$43.93M
Return on Equity (ROE)
-161.19%
TTM Avg
-40.99%
3Y Avg
-40.41%
5Y Avg
-33.61%
Market Cap
$43.68M
Return on Equity (ROE)
513.56%
TTM Avg
488.17%
3Y Avg
265.30%
5Y Avg
226.12%
Market Cap
$42.97M
Return on Equity (ROE)
-102.45%
TTM Avg
30.59%
3Y Avg
217.16%
5Y Avg
155.68%
Market Cap
$42.63M
Return on Equity (ROE)
-8.23%
TTM Avg
-18.98%
3Y Avg
-38.34%
5Y Avg
-43.89%
Market Cap
$47.83M
Return on Equity (ROE)
-17.84%
TTM Avg
-32.49%
3Y Avg
-23.88%
5Y Avg
-18.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $45.20M | -212.45% | -268.23% | -140.10% | -82.70% |
| DarioHealth Corp. (DRIO)vs › | $45.37M | 123.04% | -60.38% | -75.18% | -82.51% |
| CVRx, Inc. (CVRX)vs › | $44.32M | -260.45% | -109.97% | -78.03% | -56.14% |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $44.31M | -288.49% | -102.07% | -71.41% | -78.05% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.93M | -161.19% | -40.99% | -40.41% | -33.61% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.68M | 513.56% | 488.17% | 265.30% | 226.12% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.97M | -102.45% | 30.59% | 217.16% | 155.68% |
| Precipio, Inc. (PRPO)vs › | $42.63M | -8.23% | -18.98% | -38.34% | -43.89% |
| Precision Optics Corporation, Inc. (POCI)vs › | $47.83M | -17.84% | -32.49% | -23.88% | -18.14% |
| Lite Strategy, Inc. (LITS)vs › | $48.83M | -170.94% | -132.56% | -85.15% | -88.00% |
ROE
-212.5%
ROA
-143.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -212.45% |
| 2026-03-31 | -461.11% |
| 2025-12-31 | -245.20% |
| 2025-09-30 | -245.97% |
| 2025-06-30 | -176.40% |
| 2025-03-31 | -126.36% |
| 2024-12-31 | -96.08% |
| 2024-09-30 | -69.50% |
| 2024-06-30 | -51.65% |
| 2024-03-31 | -35.36% |
| 2023-12-31 | -33.55% |
| 2023-09-30 | -33.17% |
| 2023-06-30 | -34.53% |
| 2023-03-31 | -41.67% |
| 2022-12-31 | -43.99% |
| 2022-09-30 | -45.63% |
| 2022-06-30 | -47.41% |
| 2022-03-31 | -41.55% |
| 2021-12-31 | -32.71% |
| 2021-09-30 | -23.34% |
| 2021-06-30 | -17.53% |
| 2021-03-31 | -22.65% |
